AR077422A1 - Sales de inhibidores de plk - Google Patents
Sales de inhibidores de plkInfo
- Publication number
- AR077422A1 AR077422A1 ARP100102683A ARP100102683A AR077422A1 AR 077422 A1 AR077422 A1 AR 077422A1 AR P100102683 A ARP100102683 A AR P100102683A AR P100102683 A ARP100102683 A AR P100102683A AR 077422 A1 AR077422 A1 AR 077422A1
- Authority
- AR
- Argentina
- Prior art keywords
- salts
- counterion
- half mole
- solvates
- hydrates
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 abstract 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 abstract 2
- 150000004677 hydrates Chemical class 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 abstract 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 abstract 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 abstract 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 abstract 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 abstract 1
- 229910019142 PO4 Inorganic materials 0.000 abstract 1
- 229940077388 benzenesulfonate Drugs 0.000 abstract 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract 1
- 239000010452 phosphate Substances 0.000 abstract 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Virology (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Formas cristalinas de la base al igual que solvatos e hidratos e estas formas de sales, un proceso para su preparacion, su utilidad en terapia y las composiciones farmacéuticas que las contienen, también son reivindicadas y descritas en la presente solicitud. Reivindicacion 1: Sales del compuesto 937 con la siguiente formula caracterizadas porque son seleccionadas entre L-tartrato, succinato, fosfato, mesilato, maleato, L-malato, clorhidrato, fumarato (medio mol de contraion), fumarato, citrato (medio mol de contraion), bencenosulfonato y L-aspartato (medio mol de contraion), y sus formas cristalinas, solvatos e hidratos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09166760 | 2009-07-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR077422A1 true AR077422A1 (es) | 2011-08-24 |
Family
ID=42735665
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100102683A AR077422A1 (es) | 2009-07-29 | 2010-07-23 | Sales de inhibidores de plk |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8648078B2 (es) |
| EP (1) | EP2459196B1 (es) |
| JP (1) | JP5851990B2 (es) |
| CN (2) | CN103626777B (es) |
| AR (1) | AR077422A1 (es) |
| ES (1) | ES2553114T3 (es) |
| TW (1) | TW201109334A (es) |
| WO (1) | WO2011012534A1 (es) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK44684D0 (da) | 1984-02-01 | 1984-02-01 | Topsoee H A S | Fremgangsmaade til fremstilling af en reducerende fremgangsmade til fremstilling af en reducerende ggas as |
| US8598172B2 (en) * | 2007-12-04 | 2013-12-03 | Nerviano Medical Sciences S.R.L. | Substituted dihydropteridin-6-one derivatives, process for their preparation and their use as kinase inhibitors |
| CN102382106A (zh) * | 2010-08-30 | 2012-03-21 | 黄振华 | 苯胺取代的喹唑啉衍生物 |
| WO2012080990A1 (en) * | 2010-12-17 | 2012-06-21 | Nerviano Medical Sciences S.R.L. | Substituted pyrazolo-quinazoline derivatives as kinase inhibitors |
| JP5925808B2 (ja) * | 2011-01-26 | 2016-05-25 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | 三環式誘導体、これらの調製方法およびこれらのキナーゼ阻害剤としての使用 |
| RU2591191C2 (ru) * | 2011-01-26 | 2016-07-10 | НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. | Трициклические пирроло производные, способ их получения и их применение в качестве ингибиторов киназы |
| CN103517993A (zh) | 2011-02-28 | 2014-01-15 | 环球基因有限公司 | 用于对混合群体中的靶dna进行测序的试剂盒和方法 |
| MX368767B (es) | 2014-04-07 | 2019-10-15 | Netherlands Translational Res Center B V | (5,6-dihidro)pirimido[4,5-e]indolizinas. |
| US9684547B2 (en) | 2014-05-29 | 2017-06-20 | Apple Inc. | Method and apparatus for handling security of an application and its extension |
| EP3840741B1 (en) | 2018-08-26 | 2025-07-16 | Cardiff Oncology, Inc. | Plk1 target phosphorylation status and treatment of cancer with plk1 inhibitors |
| EP4446325A4 (en) * | 2021-12-10 | 2025-04-16 | Shandong Luye Pharmaceutical Co., Ltd. | Protein kinase inhibitors, manufacturing processes therefor and use thereof |
| EP4653443A1 (en) * | 2023-01-17 | 2025-11-26 | Phil Rivers Technology Co., Ltd | Stereoisomer and deuterated derivative of pyrazoloquinazoline compound and use |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| AU2024284206A1 (en) * | 2023-06-08 | 2025-12-11 | Shandong Luye Pharmaceutical Co., Ltd. | Salt form and crystal form of plk1 kinase inhibitor, and preparation method therefor and use thereof |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026017041A1 (zh) * | 2024-07-15 | 2026-01-22 | 北京哲源科技有限责任公司 | 一种吡唑并喹唑啉类化合物及其盐型和晶型 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4582831A (en) * | 1984-11-16 | 1986-04-15 | Pfizer Inc. | Anti-inflammatory polymorphic monoethanolamine salt of N-(2-pyridyl)-2-methyl-4-hydroxy-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide compound, composition, and method of use therefor |
| ME00142B (me) * | 2003-05-22 | 2010-10-10 | Nerviano Medical Sciences Srl | Derivati pirazolo-hinazolina, postupci za njihovo dobijanje i njihova upotreba kao inhibitora kinaze |
| WO2007090794A1 (en) * | 2006-02-10 | 2007-08-16 | Nerviano Medical Sciences S.R.L. | Combinations comprising a cdk inhibitor and a growth factor antibody or anti-mitotic |
| TW200808311A (en) * | 2006-03-30 | 2008-02-16 | Nerviano Medical Sciences Srl | Use of a kinase inhibitor for the treatment of particular resistant tumors |
| BRPI0720588B8 (pt) * | 2006-12-21 | 2021-05-25 | Nerviano Medical Sciences Srl | derivados de pirazol-quinazolina substituídos, processo para sua preparação e seu uso como inibidores da quinase |
| AR076784A1 (es) * | 2009-05-26 | 2011-07-06 | Nerviano Medical Sciences Srl | Combinacion terapeutica que comprende un inhibidor de plk1 y un agente antineoplasico |
-
2010
- 2010-07-22 US US13/387,051 patent/US8648078B2/en active Active
- 2010-07-22 CN CN201310718586.0A patent/CN103626777B/zh active Active
- 2010-07-22 CN CN2010800334619A patent/CN102470136B/zh active Active
- 2010-07-22 EP EP10737027.2A patent/EP2459196B1/en active Active
- 2010-07-22 JP JP2012522114A patent/JP5851990B2/ja active Active
- 2010-07-22 ES ES10737027.2T patent/ES2553114T3/es active Active
- 2010-07-22 WO PCT/EP2010/060659 patent/WO2011012534A1/en not_active Ceased
- 2010-07-23 TW TW099124289A patent/TW201109334A/zh unknown
- 2010-07-23 AR ARP100102683A patent/AR077422A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011012534A1 (en) | 2011-02-03 |
| ES2553114T3 (es) | 2015-12-04 |
| CN103626777A (zh) | 2014-03-12 |
| CN103626777B (zh) | 2015-10-21 |
| CN102470136A (zh) | 2012-05-23 |
| JP2013500299A (ja) | 2013-01-07 |
| HK1166015A1 (en) | 2012-10-19 |
| EP2459196B1 (en) | 2015-09-09 |
| TW201109334A (en) | 2011-03-16 |
| US20120157468A1 (en) | 2012-06-21 |
| JP5851990B2 (ja) | 2016-02-03 |
| US8648078B2 (en) | 2014-02-11 |
| EP2459196A1 (en) | 2012-06-06 |
| CN102470136B (zh) | 2013-12-25 |
| HK1195773A1 (zh) | 2014-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR077422A1 (es) | Sales de inhibidores de plk | |
| AR076433A1 (es) | Sales inhibidoras de cdk | |
| CO2022001853A2 (es) | Derivados de 2-morfolinopiridina sustituidos como inhibidores de la cinasa atr | |
| EA201001013A1 (ru) | Бис(сульфониламино)производные для применения в терапии | |
| NZ607794A (en) | N-acylsulfonamide apoptosis promoters | |
| RU2008151506A (ru) | Новые соли и кристаллические солевые формы производного 2-индолинона | |
| EA200901609A1 (ru) | Амиды пиразолкарбоновой кислоты, применимые в качестве микробиоцидов | |
| EA201000805A1 (ru) | Бис-(сульфониламино)производные в терапии 066 | |
| AR078278A1 (es) | Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro. | |
| UY31046A1 (es) | Derivados sustituidos de n-(3,4-dihidro-2h-cromen-3-il)formamida y n-(1, 2,3 ,4-tetrahidronaftalen-2-il)formamida, sales de los mismos, composiciones que los contienen, procedimientos para su preparacion y aplicaciones | |
| SG166019A1 (en) | Quinoline derivatives and use thereof as mycobacterial inhibitors | |
| EA201100030A1 (ru) | Пиразольные соединения 436 | |
| EA201100875A1 (ru) | Новые пиразол-4-n-алкоксикарбоксамиды в качестве микробиоцидов | |
| EA201270646A1 (ru) | Ингибиторы глюкозилцерамидсинтазы | |
| AR062745A1 (es) | 2-[4-(7-etil-5h-pirrolo[2,3-b]pirazin-6-il)-fenil]-propan-2-ol como inhibidor de quinasa | |
| EA201100035A1 (ru) | Производные тиазолилпиперидина | |
| CL2012000708A1 (es) | Compuestos derivados de imidazopiridina o imidazopirimidina, inhibidores de pde10a; proceso de preparacion de dichos compuestos; composiciones farmaceuticas; y su uso para el tratamiento terapeutico y/o preventivo de trastornos psicoticos, esquizofrenia, enfermedad de alzheimer, tumores solidos, entre otras enfermedades. | |
| NI201000157A (es) | Inhibidores desacetilasas b a base de hidroxamato. | |
| UY31917A (es) | Compuestos de pirido-pirimidina inhibidores de mtor, composiciones farmaceuticas que los comprenden, procesos para su preparación y su uso como medicamento. | |
| CR10206A (es) | Acidos4-fenil-tiazol-5-carboxilicos amidas de acidos 4-fenil-tiazol-5-carboxilicos como inhibidores de la plk1 | |
| UY34050A (es) | Nueva asociación entre la 4-{3-[cis-hexahidrociclopenta[c]pirrol- 2(1h)-il]propoxi}benzamida y un inhibidor de la acetilcolinesterasa y las composiciones farmacéuticas que la contienen | |
| BR112017018580A2 (pt) | p-toluenossulfonato para inibidor de mek quinase, e forma cristalina do mesmo e método de preparação para tal | |
| EP4477222A3 (en) | Crystalline 4-(5-chloro-2-isopropylaminopyridin-4-yl)-1h-pyrrole-2-carboxylic acid [1-(3-chlorophenyl)-2-hydroxyethyl]amide hydrochloride salt | |
| ECSP10010597A (es) | Nueva clase de espiro piperidinas para el tratamiento de enfermedades neurodegenerativas | |
| CR10989A (es) | Sales de adicion de acido, hidratos y polimorfos de la etil-amida del acido 5-(2,4-dihidroxi-5-isopropil-fenil)-4-(4-morfolin-4-il-metil-fenil)-isoxazol-3-carboxilico, y formulaciones que comprenden estas formas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |